BHVN Shorts Stay Heavy as Stock Surges 20%

The Street is divided, and the direction of recent analyst moves is mixed. The most relevant action was Morgan Stanley cutting its price target to $18 from $21 on May 13 while maintaining its Overweight rating — a signal of diminished conviction rather than an exit. RBC Capital trimmed to $22 earlier in the month, also keeping its Outperform. On the other side, HC Wainwright held a Neutral rating at a $10 target as recently as May 26, sitting almost exactly at the current price of $10.07. The consensus mean target of $21.71 implies substantial upside from here, but only if the pipeline delivers. The bull case rests on the breadth of Biohaven's pipeline — antibody degraders, tyrosine kinase inhibitors, programs across neuroscience and immunology — and a cash position described as sufficient to fund ongoing R&D. The bear case centres on the BHV-7000 failure in MDD, which removed one of the company's near-term value drivers and forced a strategic recalibration for 2026. EPS momentum scores reflect that caution: the 90-day reading ranks in just the 22nd percentile.

The institutional picture adds another layer of complexity. Janus Henderson holds 11.6% after a dramatic increase of over 16 million shares in the quarter ended March. BlackRock added 1.77 million shares by April 30. These are meaningful accumulations into weakness — the stock spent much of Q1 under pressure after back-to-back negative earnings reactions. The most recent prints showed a 6.7% single-day drop on May 11 and a 7.4% drop on March 2, with five-day losses of 13.9% and 11.4% respectively. On the other side, the lone gain — a 5.9% jump on a February earnings event — faded to an 11% loss by day five. The pattern of sharp post-earnings selling is consistent, and notable buyers like Janus Henderson are adding through it.

Peers had a constructive week. NRIX and BEAM each rose roughly 11-12%, and PRAX added about 9%. BHVN's 20% gain outpaced the group — suggesting either company-specific catalysts or catch-up buying from a lower base. The short score of 64 reflects an elevated but not extreme short positioning backdrop, and the ORTEX short-score rank in the 17th percentile by factor score confirms that short pressure here is heavier than most peers.

What to watch next: whether the current price, now within touching distance of HC Wainwright's $10 Neutral target, attracts further analyst re-ratings — and whether the short interest continues to build into the August earnings event or begins to cover ahead of any pipeline data readouts between now and then.